Team



Dr. Laura Soucek

laura-soucek

Co-Founder and Chief Executive Officer (CEO) of Peptomyc S.L.
Principal Investigator of the Mouse Models of Cancer Therapies Group at the Vall d´Hebron Institute of Oncology (VHIO) and ICREA Professor.

Dr. Soucek is a leading figure in the Myc field and has pioneered studies on MYC inhibition since designing Omomyc when she was still an undergraduate student. Dr. Laura Soucek has published in top scientific journals including Nature, Nature Medicine, Genes & Development, and Nature Communications as First and Senior author. Since early 2011, she heads the Mouse Models of Cancer Therapies Group at the Vall d´Hebron Institute of Oncology (VHIO), Barcelona, Spain. Although her VHIO lab is relatively young (7 years), she has already published extensively as Principal Investigator in high impact journals. Moreover, her research has already been recognized through several national research awards and grants (FERO fellowship, grants from the Miguel Servet Program, FIS and AGAUR), and prestigious international grants such as an ERC Consolidator grant (2014-2019), and an AICR (now Worldwide Cancer Research) grant. Laura is also co-inventor of two patent applications including the one at the basis of this project. In December 2014, she co-founded Peptomyc S.L. As CEO of Peptomyc S.L., she will direct the scientific aspects of the project (which is closely related to the ERC project ongoing in the lab that enabled the preliminary steps of the current innovation project) overseeing its overall implementation, progress, and success.

Relevant publications:

  1. Whitfield JR, Beaulieu ME and Soucek L (2017) Front. Cell Dev. Biol. 5:10
  2. Beaulieu ME, Jauset T, Massó-Vallés DM, Soucek L, and Whitfield JR (2017) Cancer Genetics and Genomics for Personalized Medicine. Edited by Il-Jin Kim
  3. Annibali, D., Whitfield, J.R., Favuzzi, E., Jauset, T., Serrano, E., Cuartas, I., Redondo-Campos, S., Folch, G., Gonzalez-Junca, A., Sodir, N.M., et al. (2014). Nature Communications 5, 4632.
  4. Soucek, L., Whitfield, J.R., Sodir, N.M., Masso-Valles, D., Serrano, E., Karnezis, A.N., Swigart, L.B., and Evan, G.I. (2013). Genes & Development 27, 504-513.
  5. Sodir, N.M., Swigart, L.B., Karnezis, A.N., Hanahan, D., Evan, G.I., and Soucek, L. (2011). Genes & Development 25, 907-916.
  6. Savino, M., Annibali, D., Carucci, N., Favuzzi, E., Cole, M.D., Evan, G.I., Soucek, L., and Nasi, S. (2011). PloS One 6, e22284.
  7. Soucek, L., Whitfield, J., Martins, C.P., Finch, A.J., Murphy, D.J., Sodir, N.M., Karnezis, A.N., Swigart, L.B., Nasi, S., and Evan, G.I. (2008). Nature 455, 679-683.
  8. Soucek, L., Nasi, S., and Evan, G.I. (2004). Cell Death and Differentiation 11, 1038-1045.
  9. Soucek, L., Jucker, R., Panacchia, L., Ricordy, R., Tato, F., and Nasi, S. (2002). Cancer Research 62, 3507-3510.
  10. Soucek, L., Helmer-Citterich, M., Sacco, A., Jucker, R., Cesareni, G., and Nasi, S. (1998). Oncogene 17, 2463-2472.

back to top


Dr. Marie-Eve Beaulieu

marie-eve-beaulieu

Co-Founder & Chief Scientific Officer (CSO) of Peptomyc S.L.
Senior Postdoctoral Fellow in Dr. Soucek’s Mouse Models of Cancer Therapies Group at the Vall d´Hebron Institute of Oncology (VHIO). 

Dr. Beaulieu has extensive experience in biochemistry and structural biology of b-HLH-LZ transcription factors (such as Omomyc) and peptide design. In parallel to her academic career, she worked with the pharmaceutical industry and studied peptide formulations using various biophysical methods such as Nuclear Magnetic Resonance, Circular Dichroism and Fluorescence spectroscopies. Marie-Eve graduated in November 2011 (PhD in Pharmacology, Université de Sherbrooke, Canada), and was awarded several competitive fellowships (CREFSIP scholarship grant (PhD project), MITACS Accelerated postdoctoral fellowship (postdoc project at Theratechnologies Inc., Montreal, Canada) and a FRSQ postdoctoral award from the Quebec government (current postdoc project)). She already co-authored 13 peer-reviewed publications and 2 book chapters. In 2012, she joined Dr. Soucek’s laboratory as a postdoctoral fellow and unveiled the cell-penetrating properties of the purified Omomyc peptide. She is co-inventor of the patent application protecting the use of Omomyc in medicine and co-founder of Peptomyc S.L. with the aim of translating years of academic research into a practical value for society. As CSO of Peptomyc, Marie-Eve will coordinate the activities performed by the CROs and perform and supervise the activities related to the Omomyc peptide development (preclinical validation in vitro and in vivo) within the lab.

Relevant publications:

  1. Whitfield JR, Beaulieu ME and Soucek L (2017) Front. Cell Dev. Biol. 5:10
  2. Beaulieu ME, Jauset T, Massó-Vallés DM, Soucek L, and Whitfield JR (2017) Cancer Genetics and Genomics for Personalized Medicine. Edited by Il-Jin Kim

back to top


Genesis Biomed

GENESIS Biomed is a start-up formed by entrepreneurs and with vocation of service to entrepreneurs and research centers.They have been involved as strategic consultants since the very beginning, helping the company in strategy, business development, regulatory affairs and fundraising.

 

back to top


Vantum Corporate

vantum

Vantum Corporate (CFO).

 

back to top


Peptomyc Research Team

 

Dr. Laia Foradada Felip
Laia is an experienced technician who joined Peptomyc in 2016. She has a PhD and is a qualified veterinarian, with extensive knowledge of pathology and strong technical abilities related to mouse work.

Dr. Sílvia Casacuberta Serra
Sílvia is an expert immuno-oncology scientist who joined Peptomyc in 2016 as a postdoctoral researcher. She is applying her knowledge of the immune system to investigate how Myc inhibition modulates tumor immune evasion mechanisms in different cancer models.

Toni Jauset
Toni is a final-year PhD student who has worked with Dr. Soucek since 2011. He is experienced in Myc inhibition studies, especially in lung cancer models, with a particular interest in Omomyc’s mechanisms of action and drug delivery systems.

 

back to top